NCT02419287 2023-03-06Pilot Study of Crizotinib in Relapsed ALK+ LymphomasUniversity of Milano BicoccaPhase 2 Completed12 enrolled
NCT02487316 2016-12-30A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With CrizotinibPeking UniversityPhase 4 Withdrawn